european psychiatric association

Psychopharmacology

Section committee

BITTER István , Chair

BOBES GARCIA Julio, Co-Chair

Stuhec Matej, Secretary

ERASLAN Defne, Councillor

EBERHARD Jonas, First Other Councillor



Activities

Meetings/events

Tobacco Dependence and Smoking Cessation in People with Mental Illness

Tobacco Dependence and Smoking Cessation in People with Mental Illness
Description :

Joint symposium of the Section of Addictive Behaviour and Section of Psychopharmacology: Tobacco Dependence and Smoking Cessation in People with Mental Illness Date: Monday, April 3, 2017 Time: From 08:00 to: 09:30 Hall E Chair: Marcin Wojnar, Poland Chair: Istvan Bitter, Hungary 08:00 - 08:20 EPA Guidance Paper on Tobacco Dependence and Smoking Cessation Hans-Jürgen Möller, Germany 08:20 - 08:40 Smoking Cessation and Soft Signs of Mental Disorders Tobias Rüther, Germany 08:40 - 09:00 Smoking: a Risk Factor for Suicide Henri-Jean Aubin, France 09:00 - 09:20 Is It Feasible and Effective to Help Patients with Severe Mental Disorders to Quit Smoking? Julio Bobes, Spain 09:20 - 09:30 Discussion

Partners :

Section of Addictive Behaviours

Venue :
Congress venue
Date :
April 3, 2017

Driving Ability and Psychotropic Drugs (Section Symposium)

Driving Ability and Psychotropic Drugs (Section Symposium)
Description :

Chair:  Gerd Laux, Germany 

   13:15 - 13:35 Driving Ability and Psychotropic Drugs: Introduction, Epidemiology and General Aspects

Alexander Brunnauer, Germany 

   13:35 - 13:55 Antipsychotics and Driving Ability

Carlos De las Cuevas, Spain 

   13:55 - 14:15 Antidepressants and Driving Ability

Jan Ramaekers, The Netherlands 

   14:15 - 14:35 Driving Ability and Psychotropic Drugs: Legal Framework,

Forensic Aspects

Marc Graf, Switzerland 

 14:35 - 14:45 Discussion 

 

Venue :
Congress venue
Date :
April 4, 2017

Annual meeting of the Section

Annual meeting of the Section
Description :

 Agenda:  

* Report about activities of the Section in 2016 - I Bitter
* Short summary/Follow up: EMA/CHMP consultation with Healthcare Professional Organisations/the European Psychiatric Association on the harmonisation of the indications of haloperidol and haloperidol decanoate in all EU Member States - PM Llorca/I Bitter (The report was submitted with the Annual report of the Section for 2016) 
* Topic of the Section Symposium for the next European Congress of Psychiatry (2018) - All
* Miscellaneous

Section business meeting & elections

Section business meeting & elections
Description :

1. Elections

Section had elections in Nice (5 March 2018,  17:00-18:30, Place: Room Gallieni 1) at the 26th Congress of the European Psychiatric Association (EPA 2018), 3-6 March 2018, Nice, France  with the following results:

Chair: Istvan Bitter

Co-Chair: Julio Bobes

Secretary: Matej Stuhec

Councillor: Defne Eraslan

Councillor: Jonas Eberhard

 

Prof. Hans-Jürgen Möller and Prof. Pavel Mohr collected and counted the votes.

 

2. Section meeting

Section had section meeting in Nice (5 March 2018,  17:00-18:30, Place: Room Gallieni 1) at the 26th Congress of the European Psychiatric Association (EPA 2018), 3-6 March 2018, Nice, France  with the following agenda:

 

Agenda

1.         Short Summary of the Report of the Section for the Renewal of the Contract (available on the EPA intranet)

2.         Elections of the Section officers

3.         Planning for the Congress in 2019 - All

4.         Miscellaneous – All

 

Venue :
26th European Congress of Psychiatry. Nice
Date :
5 March 2018

a) Progress and Challenges in the Antipsychotic Treatment of Schizophrenia

a)	Progress and Challenges in the Antipsychotic Treatment of Schizophrenia
Description :

26th Congress of the European Psychiatric Association (EPA 2018), 3-6 March 2018, Nice, France

Date: Monday, March 5, 2018   

Chairs:  Istvan Bitter, Hungary & Julio Bobes, Spain

 

15:00 - 15:20: The Dopamine D3 Receptor - Clinical Implications. Pierre Sokoloff, France

15:20 - 15:40: Do Antipsychotics Shrink the Brain?  Rene Kahn, USA&The Netherlands

15:40 - 16:00: Continuity of Antipsychotic Treatment in Schizophrenia

 Siegfried Kasper, Austria /Presented by Hans-Jürgen Möller, Germany

16:00 - 16:20: Have Been Too High Doses of Antipsychotics Used in

Schizophrenia?   Istvan Bitter, Hungary

16:20 - 16:30:  Discussion

 

Venue :
26th European Congress of Psychiatry. Nice
Date :
5 March 2018

b) Educational Workshop: Psychopharmacological Treatment in Elderly Patients: Chances and Gaps in Psychopharmacological Treatment

b)	Educational  Workshop: Psychopharmacological Treatment in Elderly Patients: Chances and Gaps in Psychopharmacological Treatment
Description :

26th Congress of the European Psychiatric Association (EPA 2018), 3-6 March 2018, Nice, France

(Joint Workshop of the Section of Psychopharmacology and Section of Old Age Psychiatry)

Date: Sunday, March 4, 2018   

Chairs:  Matej Stuhec, Slovenia & Julio Bobes, Spain

 

15:00 - 15:20 Sleep Inducers in Elderly Patients. What to Prescribe?

 Julio Bobes, Spain

15:20 - 15:40 How to Avoid Irrational Polypharmacy in Elderly Patients? Psychopharmacologist's View

Matej Stuhec, Slovenia

15:40 - 16:00 Drug Discontinuation in Elderly Patients. When is it Possible and Rational in Patients with Mood Disorders?

Reinhard Heun, United Kingdom

16:00 - 16:20 Clinical Aspects of Polypharmacy in Geriatric Medicine – the Role of Psychotropics  

Gerd Laux, Germany

Venue :
26th European Congress of Psychiatry. Nice
Date :
4 March 2018

c) EPA Educational session – Skating on thin ice: management of clozapine-intolerant and refractory schizophrenia patients

c)	EPA Educational session – Skating on thin ice: management of clozapine-intolerant and refractory schizophrenia patients
Description :

31st European College of Neuropsychopharmacology (ECNP) Congress, Oct 06 - 09, 2018, Barcelona, Spain.

 

Date: Sunday, October 7,  09:00 - 10:40.

Place: Room: Room 115

Moderator

Silvana Galderisi, Italy

Presentations

09:05-09:50. E.02.01: Treatment options for clozapine-intolerant and refractory schizophrenia patients. Istvan Bitter, Hungary

09:50-10:35. E.02.02: Needs of patients with treatment resistant schizophrenia – can mobile phone applications help? Iluminada Corripio, Spain

Venue :
31st European College of Neuropsychopharmacology (ECNP) Congress
Date :
7 October 2018

Publications

A proposal for a psychopharmacology-pharmacotherapy catalogue of learning objectives and a curriculum in Europe.

<p><a href="https://www.pubfacts.com/detail/26850137/A-proposal-for-a-psychopharmacology-pharmacotherapy-catalogue-of-learning-objectives-and-a-curriculu">A proposal for a psychopharmacology-pharmacotherapy catalogue of learning objectives and a curriculum in Europe.</a></p>
Journal :
World J Biol Psychiatry 2017 Feb 6;18(1):29-38. Epub 2016 Apr 6
Acknowledged as official Section publication ? Yes

Other Section activities


Desciption :

Section responded to some questions and questionnaires related to psychopharmacology at the request of the President and/or Secreatriat of EPA (e.g. the distribution of a pharmacigenetoc darabase: "The EPA has been contacted by the Royal Dutch Pharmacists Association which is asking to endorse pharmacogenomic guidelines developed within the U-PGx project funded under the Horizon2020. These guidelines are available for over 90 drugs. For more information, please refer to the email below and the project’s website: http://upgx.eu<http://upgx.eu/>." ; some questions from EMA).

Time period : 2018

Calendar of Future Activities

EPA Congress 2019 Warsaw sessions - Other

EPA Congress 2019 Warsaw sessions - Other
Desciption :

The following activities are planned by the section in 2019:

  1. InterACT e-newsletter (will be published in 2019)
  2. Symposia

 

27th European Congress of Psychiatry (EPA 2019) will take place between 6 and 9 April 2019 in Warsaw, Poland

 

Monday, April 8th, 17:00 - 18:30, Hall B

Session title: Symposium: Diagnosis and Management of Treatment-Resistant Psychiatric Disorders

Session type:Clinical/Therapeutic (Proposed by the EPA Section on Psychopharmacology)

Chairs: Istvan Bitter, Hungary & Julio Bobes Garcia, Spain

17:00 - 17:20: Can a Better Classification of Psychiatric Drugs Reduce Treatment Resistance?

H. Möller, Munich, Germany.

17:20 - 17:40: Evaluating and Managing Treatment-Resistant Schizophrenia.

P. Mohr, Klecany, Czech Republic.

17:40 - 18:00: Adult ADHD and Substance Use as Comorbid Conditions in Treatment Resistant Psychiatric Disorders. Josep Antoni Ramos-Quiroga, Spain

18:00 - 18:20: Progress in the Treatment of Treatment-Resistant Depression. S. Kasper, Vienna, Austria.

18:20 - 18:30: Discussion

 

 

 

Tuesday, April 9th, 08:00 - 09:30, Hall C

Session title: Workshop: Drug-Drug Interactions in Real Clinical Practice in Elderly Patients with Mental Disorders: How to Avoid?

Session type: Educational (Proposed by the EPA Section on Old Age Psychiatry and EPA Section on Psychopharmacology)

Chairs: Matej Stuhec, Slovenia  & Julio Bobes Garcia, Spain

 

 08:00 - 08:16: A Pharmacokinetic and Pharmacodynamic Overview of Potential and Clinically Important Drug-Drug Interactions. Matej Stuhec, Slovenia.

08:16 - 08:32: Important Drug-Drug Interactions of Antidepressants. Gerd Laux, Germany

08:32 - 08:48:Important Drug-Drug Interactions of Antipsychotics. J. Bobes Garcia, Spain.

08:48 - 09:04: How to Avoid Inappropriate Drug Treatments and Drug-Drug Interactions in Dementia. G. Stoppe, Switzerland.

09:04 - 09:20: How to Recognize Drug-Drug Interactions with Therapeutic Drug Monitoring. P. Baumann, Switzerland.

09:20 - 09:30: Discussion